NCT06041503View on ClinicalTrials.gov

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
Adenocarcinoma of the BladderSquamous Cell Carcinoma of the BladderTesticular Germ Cell Tumors
Interventions
DRUG

Pembrolizumab

Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.

DRUG

Enfortumab vedotin

EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH